Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IVIG versus prophylactic co-trimoxazole in patients with recurrent infections and IgG subclass deficiency and/or deficient antipolysaccharide antibody response
2006-005215-98Phase 4Active
- Sponsor
- Sanquin Plasma Products
- Start
- Aug 2007
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of Nanogam and trimethoprim + sulfamethoxazole in IgG subclass deficiency (IgGSD) and selective antibody deficiency (SAD) (2 arms), sponsored by Sanquin Plasma Products. Primary endpoints: Number of infections, Duration of infections and 5 more. Started Aug 2007; status: active.
02
Drugs
Nanogamtrimethoprim + sulfamethoxazole
03
Conditions
IgG subclass deficiency (IgGSD)selective antibody deficiency (SAD)
Beyond the preview
Go deeper on 2006-005215-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005215-98.